Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide

A study published in the Journal of Clinical Oncology examined patterns of radiographic progression in patients with advanced prostate cancer receiving enzalutamide, distinguishing between cases with and without a concurrent rise in prostate-specific antigen (PSA). The research provides important insights into how disease progression manifests differently in patients on androgen receptor-targeted therapy, where PSA may not always reliably signal worsening disease. These findings have clinical implications for monitoring strategies and treatment decision-making in men with advanced prostate cancer on enzalutamide. The work underscores the need for continued imaging surveillance regardless of PSA kinetics in this patient population.